Home » Stocks » HJLI

Hancock Jaffe Laboratories, Inc. (HJLI)

Stock Price: $0.360 USD 0.012 (3.45%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
After-hours: $0.360 0.000 (-0.03%) Oct 28, 7:48 PM

Stock Price Chart

Key Info

Market Cap 8.62M
Revenue (ttm) n/a
Net Income (ttm) -6.89M
Shares Out 23.95M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $0.360
Previous Close $0.348
Change ($) 0.012
Change (%) 3.45%
Day's Open 0.367
Day's Range 0.345 - 0.379
Day's Volume 2,328,972
52-Week Range 0.211 - 0.850

More Stats

Market Cap 8.62M
Enterprise Value 7.27M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 23.95M
Float 22.96M
EPS (basic) -0.37
EPS (diluted) -0.36
FCF / Share -0.27
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.25M
Short Ratio 0.56
Short % of Float 5.42%
Beta 1.74
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 50.50
Revenue n/a
Operating Income -7.19M
Net Income -6.89M
Free Cash Flow -5.76M
Net Cash 1.35M
Net Cash / Share 0.06
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -75.08%
ROE -274.52%
ROIC 14,025.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$2.10*
Low
2.10
Current: $0.360
High
2.10
Target: 2.10
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue0.030.190.420.79
Revenue Growth-83.25%-55.8%-46.29%-
Gross Profit0.030.19--0.02
Operating Income-7.68-7.85-6.10-4.66
Net Income-7.63-13.04-7.79-3.39
Shares Outstanding15.769.366.136.04
Earnings Per Share-0.48-1.75-1.35-0.62
Operating Cash Flow-5.90-6.36-4.20-3.42
Capital Expenditures-0.36-0.01-0.01-
Free Cash Flow-6.26-6.37-4.21-3.42
Cash & Equivalents2.122.740.080.06
Total Debt0.86-2.620.63
Net Cash / Debt1.262.74-2.54-0.58
Assets3.433.562.211.78
Liabilities2.441.528.172.07
Book Value0.992.04-11.13-4.22
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Hancock Jaffe Laboratories, Inc.
Country United States
Employees 12
CEO Robert Andrew Berman

Stock Information

Ticker Symbol HJLI
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: HJLI

Description

Hancock Jaffe Laboratories, a development stage company, develops and sells biological based tissue solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. The company develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat chronic venous insufficiency; the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries; and the Bioprosthetic Heart Valve, a porcine based heart valve designed to function like a native heart valve used for pediatric heart valve recipients. It also provides research, development, and contract manufacturing services. Hancock Jaffe Laboratories, Inc. was founded in 1987 and is based in Irvine, California.